MARKET

PHAT

PHAT

Phathom Pharmaceuticals, Inc.
NASDAQ
10.72
+0.38
+3.68%
After Hours: 10.66 -0.06 -0.56% 19:48 06/26 EDT
OPEN
10.43
PREV CLOSE
10.34
HIGH
10.78
LOW
10.11
VOLUME
2.66M
TURNOVER
--
52 WEEK HIGH
18.31
52 WEEK LOW
7.61
MARKET CAP
854.98M
P/E (TTM)
-5.0779
1D
5D
1M
3M
1Y
5Y
1D
Analysts Conflicted on These Healthcare Names: Phathom Pharmaceuticals (PHAT) and Elicio Therapeutics (ELTX)
TipRanks · 2d ago
Phathom Pharma Completes Enrollment In Phase 2 PHalcon-EoE-201 For Eosinophilic Esophagitis
NASDAQ · 3d ago
Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial
TipRanks · 4d ago
Phathom Completes Enrollment in Eosinophilic Esophagitis Trial
TipRanks · 4d ago
Phathom Pharmaceuticals Completes Patient Enrollment In Its Phase 2 pHalcon-EoE-201 Clinical Study Of VOQUEZNA Tablets To Treat Eosinophilic Esophagitis In Adults
Benzinga · 4d ago
Phathom completes enrollment in Phase 2 VOQUEZNA trial for eosinophilic esophagitis in adults
PUBT · 4d ago
PHATHOM PHARMACEUTICALS - TOPLINE RESULTS FROM PHASE 2 TRIAL EXPECTED IN Q4 2026
Reuters · 4d ago
Weekly Report: what happened at PHAT last week (0615-0619)?
Weekly Report · 5d ago
More
About PHAT
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of novel treatments for gastrointestinal diseases. It has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the United States (U.S.), Europe and Canada. PCABs are a novel class of molecules that block acid secretion in the stomach. The Company markets vonoprazan in the U.S. as VOQUEZNA (vonoprazan) tablets for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (Non-Erosive GERD) in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults.

Webull offers Phathom Pharmaceuticals Inc stock information, including NASDAQ: PHAT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHAT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PHAT stock methods without spending real money on the virtual paper trading platform.